Antibiotice Ia (ATB) — Capital Reinvestment Ratio
Antibiotice Ia (ATB) has a Capital Reinvestment Ratio of 0.35x as of December 2025, meaning it reinvests 0% of its operating cash flow (RON37.61 Million) in capital expenditures (RON13.33 Million). See debt-free asset ratio of Antibiotice Ia to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Antibiotice Ia Capital Reinvestment Ratio (2022–2025)
This chart tracks Antibiotice Ia's Capital Reinvestment Ratio across 4 annual periods. Check cash flow reinvestment rate of Antibiotice Ia to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Antibiotice Ia (2022–2025)
Year-by-year Capital Reinvestment Ratio for Antibiotice Ia from 2022 to 2025. For live market cap and broader valuation context, see ATB market cap.
| Year | Reinvestment Ratio | Operating CF (RON) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 1.97x | RON72.44 Million | RON142.61 Million | ▲ +61.3% |
| 2024 | 1.22x | RON95.15 Million | RON116.16 Million | ▲ +52.5% |
| 2023 | 0.80x | RON122.46 Million | RON98.04 Million | ▲ +132.2% |
| 2022 | 0.34x | RON115.66 Million | RON39.88 Million | — |